Thumbnail Image
Publication

Brigatinib vs crizotinib in patients with ALK inhibitor-naive advanced ALK plus NSCLC: first report of a phase 3 trial (ALTA-1L)

Camidge, R
; 
Kim, H
; 
Ahn, M
; 
Yang, J
; 
Han, J
; 
Lee, J
; 
Hochmair, M
; 
Li, J
; 
Chang, G
; 
Lee, K
... show 10 more
Citations
Altmetric:
Abstract
Authors
Camidge, R
Kim, H
Ahn, M
Yang, J
Han, J
Lee, J
Hochmair, M
Li, J
Chang, G
Lee, K
Gridelli, C
Delmonte, A
Campelo, M
Kim, D
Bearz, A
Griesinger, F
Morabito, A
Felip, E
Califano, Raffaele
Ghosh, S
Spira, A
Gettinger, S
Tiseo, M
Haney, J
Kerstein, D
Popat, S
Affiliation
University of Colorado Cancer Center, Aurora, CO/US
Description
Date
2018
Publisher
Collections
All Christie Publications
Show all metadata
Keywords
Type
Meetings and Proceedings
Citation
Camidge R, Kim HR, Ahn M, Yang JC, Han J, Lee J, et al. PL02.03 Brigatinib vs crizotinib in patients with ALK inhibitor-naive advanced ALK plus NSCLC: first report of a phase 3 trial (ALTA-1L)). J Thorac Oncol. 2018;13(10):S184-S185.
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/621511
Embedded videos